QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies

HILDEN, Germany, October 25, 2012 /PRNewswire/ –

        - QIAGEN and Bayer HealthCare signed collaboration agreement aimed at
          advancing both companies positions in personalized medicine
        - The programs pair QIAGEN companion diagnostic solutions with innovative
          targeted therapies for patients with solid tumors developed by Bayer HealthCare
        - Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today
announced a collaboration agreement for the development and commercialization of companion
diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment
of various solid tumors. Companion diagnostics are tests that unlock molecular information
from each patient’s tumor genome to guide treatment decisions with medications for cancers
or other diseases. The parties will also collaborate on the development of novel
technologies for patient profiling which may result in innovative research-use-only
products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family
of automated instruments, which is transforming laboratory workflows and helping
disseminate standardized, regulator-approved diagnostics.

“We are very pleased to partner with Bayer HealthCare in developing companion
diagnostics to improve life for cancer patients. As healthcare providers increasingly
select the right drugs based on each individual’s genomic information, the treatment of
cancer is undergoing a revolution,” said Dr. Helge Lubenow, Senior Vice President
Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. “The
first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics based
on the identification of patients who may respond to therapies in clinically unmet disease
classifications. Our agreement also lays the groundwork for a strong partnership in
creating future companion diagnostics both inside and outside of oncology.”

“Partnering with QIAGEN on companion diagnostics will help Bayer HealthCare to develop
innovative therapies, enabling physicians to analyze DNA and proteins from each patient.
This helps to design more efficient clinical trials and to increase the overall
probability of therapeutic success for patients suffering from cancer,” said Prof. Dr.
Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of
Bayer HealthCare.

QIAGEN is a leading partner globally in developing and validating companion
diagnostics to guide the selection of medicines in treating cancer and other diseases. In
July 2012, QIAGEN received FDA approval for the therascreen(R) KRAS RGQ PCR
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=355&lang=EN ]
Kit as a companion diagnostic in patients with metastatic colorectal cancer. The U.S.
rollout of therascreen KRAS builds on a strong global leadership position which includes
successes in Japan, where regulators approved the therascreen KRAS and EGFR kits in 2011
and in Europe, where QIAGEN offers 10 CE-marked assays for personalized healthcare
applications.

In addition to the Bayer HealthCare collaboration, QIAGEN has more than 15 projects
under way to co-develop and market companion diagnostics with leading pharmaceutical and
biotech companies.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative
companies in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health, Consumer Care,
Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover,
develop, manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and
is represented in more than 100 countries. More information at

http://www.healthcare.bayer.com.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample &
Assay Technologies that are used to transform biological materials into valuable molecular
information. Sample technologies are used to isolate and process DNA
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
, RNA
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
and proteins from biological samples such as blood or tissue. Assay technologies are
then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN
markets more than 500 products around the world, selling both consumable kits and
automation systems to customers through four customer classes: Molecular Diagnostics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
(human healthcare), Applied Testing
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
(forensics, veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of June 30, 2012,
QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended.
To the extent that any of the statements contained herein relating to QIAGEN’s products,
markets, strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating results and allocations
between customer classes, the commercial development of markets for our products in
applied testing
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
, personalized healthcare, clinical research, proteomics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
, women’s health/HPV
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
testing and nucleic acid
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
-based molecular diagnostics
[http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=384&lang=EN ]
; changing relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products
(including fluctuations due to general economic conditions, the level and timing of
customers’ funding, budgets and other factors); our ability to obtain regulatory approval
of our products; difficulties in successfully adapting QIAGEN’s products to integrated
solutions and producing such products; the ability of QIAGEN to identify and develop new
products and to differentiate and protect our products from competitors’ products; market
acceptance of QIAGEN’s new products, the consummation of acquisitions, and the integration
of acquired technologies and businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities
and Exchange Commission (SEC).

        Contacts:

        Public Relations:
        Dr. Thomas Theuringer
        Director Public Relations
        +49-2103-29-11826
        +1-240-686-7425
        Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/about/press

        Investor Relations:
        John Gilardi
        VP Corporate Communications
        +49-2103-29-11711
        +1-240-686-2222

        Albert F. Fleury
        Investor Relations North America
        +1-240-686-7400
        Email: ir@qiagen.com

http://www.qiagen.com/about/investorrelation

SOURCE Qiagen N V